Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. Our innovation /
      3. Focus areas/
      4. Neuroscience /
      5. Neurological & neuromuscular disorders
      neuroscience.jpg
      Neuroscience

      Neurological & neuromuscular disorders

      June 18, 2024
      1 min read

      As part of our strategy to broaden our focus beyond neuropsychiatry, we acquired Momenta Pharmaceuticals and gained full rights to an anti-neonatal Fc receptor monoclonal antibody that has the potential to address a range of serious autoantibody-mediated autoimmune diseases, including certain neurologic and neuromuscular disorders. Significant unmet treatment needs remain in these disease areas, despite standard of care treatment options available.[6]

      We are committed to deepening our research in neurologic and neuromuscular conditions to help address the significant unmet need for therapies and treatments for patients. This acquisition also enhanced our pathway-based research and development approach across therapeutic areas.

      References

      [1]Deuschl G, et al. The burden of neurological diseases in Europe: An analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10):E551-E567.

      [2]Open Access Government 2019. Tackling the growing burden of brain disorders in Europe. Available at: https://www.openaccessgovernment.org/brain-disorders-in-europe/72909/. Last accessed July 2023.

      [3]GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018;392:1789-1858.

      [4]PsychGuides.com. Neurological Problem Symptoms, Causes and Effects. Available at: https://www.psychguides.com/neurological-disorders/. Last accessed July 2023.

      [5]WHO. Depression and other common mental disorders. Available at: WHO-MSD-MER-2017.2-eng.pdf Last accessed July 2023.

      [6]WHO. Fact sheets. Depression. Available at https://www.who.int/news-room/fact-sheets/detail/depression. Last accessed July 2023.

      [7]Machado-Viera R, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals. 2010;3(1):19–41.

      [8]Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges and future directions. Patient Pref Adherence. 2012;6:369–388.

      [9]Demyttenaere K & Van Duppen D. The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review. Int J Neuropsychopharmacol 2019;22(2):85–92.

      [10]Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17.

      [11]Heerlein K, Perugi G, Otte C, et al. Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes. J Affect Disord. 2021;290:334-344.